FR2466252A2 - Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine - Google Patents

Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine Download PDF

Info

Publication number
FR2466252A2
FR2466252A2 FR7924655A FR7924655A FR2466252A2 FR 2466252 A2 FR2466252 A2 FR 2466252A2 FR 7924655 A FR7924655 A FR 7924655A FR 7924655 A FR7924655 A FR 7924655A FR 2466252 A2 FR2466252 A2 FR 2466252A2
Authority
FR
France
Prior art keywords
sep
chain
antibody
solution
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7924655A
Other languages
English (en)
French (fr)
Other versions
FR2466252B2 (de
Inventor
Guy Andre Voisin
Franz Klaus Jansen
Pierre Gros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CM Industries SA
Clin Midy
Original Assignee
CM Industries SA
Clin Midy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CM Industries SA, Clin Midy filed Critical CM Industries SA
Priority to FR7924655A priority Critical patent/FR2466252A2/fr
Publication of FR2466252A2 publication Critical patent/FR2466252A2/fr
Application granted granted Critical
Publication of FR2466252B2 publication Critical patent/FR2466252B2/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR7924655A 1979-10-03 1979-10-03 Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine Granted FR2466252A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7924655A FR2466252A2 (fr) 1979-10-03 1979-10-03 Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7924655A FR2466252A2 (fr) 1979-10-03 1979-10-03 Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine

Publications (2)

Publication Number Publication Date
FR2466252A2 true FR2466252A2 (fr) 1981-04-10
FR2466252B2 FR2466252B2 (de) 1983-08-12

Family

ID=9230281

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7924655A Granted FR2466252A2 (fr) 1979-10-03 1979-10-03 Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine

Country Status (1)

Country Link
FR (1) FR2466252A2 (de)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010A1 (fr) * 1981-04-15 1982-10-22 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
FR2516794A1 (fr) * 1981-11-20 1983-05-27 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
EP0088694A1 (de) * 1982-03-10 1983-09-14 Elf Sanofi Zellgiftiges Arzneimittel enthaltend mindestens ein Immunotoxin und Chloroquin
EP0089270A1 (de) * 1982-03-11 1983-09-21 Elf Sanofi Zellgiftiges Arzneimittel enthaltend mindestens ein Immunotoxin und ein Amin
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
FR2566271A1 (fr) * 1984-06-20 1985-12-27 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
EP0248040A4 (de) * 1985-11-29 1988-01-07 Univ Melbourne Ricin-antikörper-konjugate.
EP0306943A3 (en) * 1987-09-10 1989-11-15 Neorx Corporation Immunconjugates joined by thioether bonds having reduced toxicity and improved selectivity
EP1040098A4 (de) * 1997-12-17 2002-10-30 Merck & Co Inc Integrin-rezeptor-antagonisten

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319473A1 (de) * 1973-04-17 1974-11-07 Eisai Co Ltd Ricinhaltiges pharmazeutisches material mit antikrebswirkung
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319473A1 (de) * 1973-04-17 1974-11-07 Eisai Co Ltd Ricinhaltiges pharmazeutisches material mit antikrebswirkung
DE2456224A1 (de) * 1974-11-28 1976-08-12 Karl Dr Med Theurer Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie
GB1446536A (en) * 1975-02-21 1976-08-18 Yeda Res & Dev Pharmaceutically active compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA1979 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010A1 (fr) * 1981-04-15 1982-10-22 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
EP0063988A1 (de) * 1981-04-15 1982-11-03 Sanofi S.A. Mit einem Antimelanoma-Antikörper verbundene Ricin-A-Kette enthaltende Antikrebs-Heilmittel und Verfahren zu ihrer Herstellung
FR2516794A1 (fr) * 1981-11-20 1983-05-27 Sanofi Sa Nouveaux medicaments anticancereux pour le traitement des leucemies t constitues de la chaine a de la ricine et d'un anticorps monoclonal specifique
EP0080401A1 (de) * 1981-11-20 1983-06-01 Elf Sanofi Krebshemmende Heilmittel für die Behandlung von T-Leukämien, bestehend aus der A-Kette des Rizinus und einem spezifischen monoklonalen Antikörper
EP0088694A1 (de) * 1982-03-10 1983-09-14 Elf Sanofi Zellgiftiges Arzneimittel enthaltend mindestens ein Immunotoxin und Chloroquin
WO1983003055A1 (fr) * 1982-03-10 1983-09-15 Jansen, Franz Medicament cytotoxique forme de l'association d'au moins une immunotoxine et de la chloroquine
FR2536997A1 (fr) * 1982-03-11 1984-06-08 Sanofi Sa Medicaments cytotoxiques comportant au moins une immunotoxine et de la methylamine
WO1983003200A1 (fr) * 1982-03-11 1983-09-29 Jansen, Franz Medicaments cytotoxiques comportant au moins une immunotoxine et une amine
EP0089270A1 (de) * 1982-03-11 1983-09-21 Elf Sanofi Zellgiftiges Arzneimittel enthaltend mindestens ein Immunotoxin und ein Amin
US4614650A (en) * 1982-03-11 1986-09-30 Sanofi Cytotoxic composition including at least an immunotoxine and an amine
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
EP0130132A1 (de) * 1983-06-27 1985-01-02 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Antitumor-Immunotoxin, pharmazeutische Zubereitungen die sie enthalten, und ihre Verwendung in vitro
FR2566271A1 (fr) * 1984-06-20 1985-12-27 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
EP0169111A1 (de) * 1984-06-20 1986-01-22 Sanofi Therapeutisch verwendbare zytotoxische Konjugate und Verfahren zu deren Herstellung
EP0269188A3 (en) * 1984-06-20 1988-08-31 Sanofi Cytotoxic conjugates useful in therapy, and process for obtaining them
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
EP0248040A4 (de) * 1985-11-29 1988-01-07 Univ Melbourne Ricin-antikörper-konjugate.
EP0306943A3 (en) * 1987-09-10 1989-11-15 Neorx Corporation Immunconjugates joined by thioether bonds having reduced toxicity and improved selectivity
EP1040098A4 (de) * 1997-12-17 2002-10-30 Merck & Co Inc Integrin-rezeptor-antagonisten

Also Published As

Publication number Publication date
FR2466252B2 (de) 1983-08-12

Similar Documents

Publication Publication Date Title
EP0063988B1 (de) Mit einem Antimelanoma-Antikörper verbundene Ricin-A-Kette enthaltende Antikrebs-Heilmittel und Verfahren zu ihrer Herstellung
EP0080401B1 (de) Krebshemmende Heilmittel für die Behandlung von T-Leukämien, bestehend aus der A-Kette des Rizinus und einem spezifischen monoklonalen Antikörper
CH647411A5 (fr) Procede de preparation de produits cytotoxiques.
EP0089880B1 (de) Kovalente Konjugate,die ein Enzym und einen Antikörper verbinden und medikamentöse Zubereitungen,die diese Konjugate enthalten
DE69637383T2 (de) Cytotoxinkonjugate umfassend dipeptide
DE69730332T2 (de) Alkyldextran-polyalcohol Arzneimittel-Komplexe
EP0057140B1 (de) Thioliertes Polypeptid aus einem Fragment des tetanischen Toxins, Verfahren zu seiner Herstellung und seine Anwendungen
HU189469B (en) Process for preparing antitumour immunoglobulin-derivatives with antibody effect, comprising ricin a subordinate unit
BG63492B1 (bg) Методи за получаване на мономерни конюгати калихеамициново производно/носител
JP2001500133A (ja) トランスフェリン、アルブミン及びポリエチレングリコールの抗腫瘍性の複合体
EP0328446A1 (de) Konjugate von in Position C-3 eine Detergens-Kette enthaltenden Vinca-Derivaten
JPS59116232A (ja) 細胞毒性複合体及びその製造法
CN111686259A (zh) 一种含sn38的抗体药物偶联物
EP0037388B1 (de) Pharmazeutische Stoffe, deren Herstellung und Präparate in denen diese enthalten sind
EP0255424B1 (de) Immunotoxine, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
FR2550944A1 (fr) Association pharmaceutique a base d'anticorps anticellules tumorales et de conjugues cytotoxiques, appropriee notamment pour le traitement des cancers
EP0192002B1 (de) Langwirkende Immunotoxine, die eine ribosominaktivierende, an ihren Polysaccharidstellen modifizierte Glycopeptidsubstanz umfassen
EP0162781B1 (de) Conjugierte Derivate, assoziiert durch covalente Bindungen mit einem monovalenten Carbonylionophor, ihre Verwendung als Potentialisatoren von Immunotoxinen und activierte ionophore Zwischenverbindungen
EP0172045A1 (de) Antitumorglycoproteine welche an ihren Kohlenhydratteilen modifiziert sind und Verfahren zu deren Herstellung
US4582703A (en) Cytotoxic medicament formed from the association of at least one immunotoxin and chloroquin
FR2543970A1 (fr) Anticorps vis-a-vis de champignons du genre aspergillus
EP0234151A1 (de) Die Ribosome inhibierende, mittels Oxidation und Bildung von Schiffbasen modifizierte Glukoproteine, Verfahren zur Herstellung derselben und ein solches Glukoprotein enthaltende Immunotoxine
FR2701710A1 (fr) Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic.
FR2601680A1 (fr) Inhibiteur de la synthese proteique, procede d'isolement, utilisation et compositions pharmaceutiques en contenant
EP0386045B1 (de) Derivate von synergimycinen a und b

Legal Events

Date Code Title Description
TP Transmission of property